Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?

1kṀ1142

resolved Jan 7

Resolved

YES

ALL

The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?

Market context

Get

1,000

to start trading!

🏅 Top traders

#	Name	Total profit
1		Ṁ32
2		Ṁ26
3		Ṁ17
4		Ṁ14
5		Ṁ14

People are also trading

Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?

41% chance

Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

30% chance

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

84% chance

Will a majority government owned company introduce a new GLP-1 drug before 2040?

15% chance

Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?

71% chance

By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?

86% chance

Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms

68% chance

Before 2033, will semaglutide be shown to improve lifespan, when prescribed to overweight people?

83% chance

Nobel Prize awarded for Ozempic (or GLP-1 drugs) by 2030?

46% chance

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

Sort by:

I'm double-checking medical journals this week. It's not as straightforward as you might think. One of the two studies linked below was not published in 2024 but in 2023. Have a bit more patience, please. (Not inactive, Paper, just traveling.)